뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - glucagon hydrochloride 1mg (recombinant);  ;   - solution for injection - 1 mg - active: glucagon hydrochloride 1mg (recombinant)     excipient: lactose monohydrate water for injection - therapeutic treatment of severe hypoglycaemic reactions, which may occur in the management of diabetic patients receiving insulin or oral hypoglycaemic agents. to prevent the occurrence of secondary hypoglycaemia, oral carbohydrate should be given to restore the hepatic glycogen when the patient has responded to the treatment. the mechanism and hence treatment of sulfonylurea-induced hypoglycaemia differs from that of severe insulin-induced hypoglycaemia in some important ways. consciousness should preferably be restored by the administration of intravenous glucose. if glucagon is used due to the unavailability of intravenous glucose (e.g. before reaching a hospital) care should be taken to protect against secondary hypoglycaemia with constant monitoring of the patient's blood sugar level by medical personnel. subsequent administration of intravenous glucose may be required.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - somatropin -

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - somatropin -

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - somatropin -

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - semaglutide, quantity: 7 mg - tablet - excipient ingredients: microcrystalline cellulose; povidone; magnesium stearate; salcaprozate sodium - rybelsus is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. ? as monotherapy if metformin is considered inappropriate due to intolerance or contraindications; or ? in combination with other medicinal products for the treatment of type 2 diabetes mellitus.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - semaglutide, quantity: 3 mg - tablet - excipient ingredients: microcrystalline cellulose; povidone; magnesium stearate; salcaprozate sodium - rybelsus is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. ? as monotherapy if metformin is considered inappropriate due to intolerance or contraindications; or ? in combination with other medicinal products for the treatment of type 2 diabetes mellitus.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - semaglutide, quantity: 14 mg - tablet - excipient ingredients: microcrystalline cellulose; povidone; magnesium stearate; salcaprozate sodium - rybelsus is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. ? as monotherapy if metformin is considered inappropriate due to intolerance or contraindications; or ? in combination with other medicinal products for the treatment of type 2 diabetes mellitus.

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - insulin detemir 100 u/ml - solution for injection - 100 u/ml - active: insulin detemir 100 u/ml excipient: dibasic sodium phosphate dihydrate glycerol hydrochloric acid metacresol phenol sodium chloride sodium hydroxide water for injection zinc - for the treatment of diabetes mellitus

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin - human; human insulin -

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin - human; human insulin -